Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)

Completed · Phase 4

Conditions studied: Contraception

In brief

The purpose of this research study is to help in the development of safe, effective and reversible male contraception. We are examining the impact of the drug Miglustat on sperm production in normal men. We want to see if Miglustat will inhibit sperm production in men and act as a reversible male contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of sperm production. We believe Miglustat may have some potential as a safe, reversible male contraceptive.

Key facts

Study ID

NCT00194649

Run by

University of Washington

People needed

8

Starts

2005-06-01

Expected to finish

2006-01-01

Last updated by the study team

2008-09-19

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy male, normal lab test

You may not qualify if…

• Abnormal lab test, history or evidence of significant chronic or acute medical illness, previous or current ethanol or anabolic steroid abuse.

Where it is running

• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.